Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed/refractory acute myeloid leukemia

Yuchen Liu, Dominique R Bollino, Osman M Bah, Erin T Strovel, Tien Van Le, Jinoos Zarrabi, Sunita Philip, Rena G Lapidus, Maria R Baer, Sandrine Niyongere, Vu H. Duong, Christine C Dougherty, Jan Hendrik Beumer, Katherine D Caprinolo, Farin Kamangar, Ashkan Emadi

Blood blood.2024024837.

https://doi.org/10.1182/blood.2024024837

Published: 2024

Includes: Supplemental data

Journal Articles

Overcoming Venetoclax (Ven) Resistance through Glutamine (Gln) Depletion: Final Analysis of the Phase 1 Trial of Ven and Pegcrisantaspase (PegC) Combination in Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML)

Yuchen Liu, Dominique Bollino, Osman M Bah, Erin T Strovel, Jinoos Zarrabi, Sunita Philip, Ezzat Mostafa, Rena G Lapidus, Maria R. Baer, Sandrine Niyongere, Vu H. Duong, Christine C Dougherty, Katherine Caprinolo, Ashkan Emadi

Blood (2023) 142 (Supplement 1): 60.

https://doi.org/10.1182/blood-2023-186244

Published: 2023

Journal Articles

Targeting the JAK2V617F Hematopoietic Stem Cell through Beta1 Integrin

Shinobu Matsuura, Siyang Long, Iris Karkempetzaki, Aikaterini Karagianni, Xiaosheng Yang, Nasi Huang, Yuchen Liu, Chao Zhang, Katya Ravid

Blood (2023) 142 (Supplement 1): 4517.

https://doi.org/10.1182/blood-2023-186090

Published: 2023

Journal Articles

Phase 1 Dose Escalation Trial of Pegcrisantaspase in Combination with Venetoclax in Adults with Relapsed or Refractory Acute Myeloid Leukemia

Dominique R Bollino, Yuchen Liu, Osman Mohamed Bah, Katherine Caprinolo, Jinoos Zarrabi, Sunita Philip, Ezzat Mostafa, Rena G. Lapidus, Zeba Singh, Michael Kallen, Yi Ning, Rima Koka, Maria R. Baer, Sandrine Niyongere, Vu H. Duong, Erin T Strovel, Molly Graveno, Ashkan Emadi

Blood (2022) 140 (Supplement 1): 9044–9045.

https://doi.org/10.1182/blood-2022-159621

Published: 2022

Journal Articles

Sequential GD2 Chimeric Antigen Receptor T Cell Therapy (4SCAR2.0-GD2) for the Treatment of Refractory/Relapsed Neuroblastoma

Yuchen Liu, Jingfu Wang, Suyi Kang, Rui Zhang, Lung-Ji Chang

Blood (2022) 140 (Supplement 1): 7462–7463.

https://doi.org/10.1182/blood-2022-164461

Published: 2022

Journal Articles

Pro-Active 4SCAR2.0 Therapy with NGS-MRD Disease Monitoring in High-Risk B Cell Leukemia Management

Cheng Jiao, Yuchen Liu, Rui Zhang, Weihong Chen, Lung-Ji Chang

Blood (2022) 140 (Supplement 1): 12744–12745.

https://doi.org/10.1182/blood-2022-159884

Published: 2022

Journal Articles

Improved Lentiviral In Vivo Gene Therapy for Chronic Granulomatous Disease

Haokun Yuan, Hongwei Liu, Xiaomei Wu, Yuchen Liu, Rui Zhang, Lung-Ji Chang

Blood (2022) 140 (Supplement 1): 4921–4922.

https://doi.org/10.1182/blood-2022-159862

Published: 2022

Journal Articles

Intravenous Lentiviral Gene Therapy for Hemophilia a: Endothelial-Specific Expression and Increased Glycosylation for Improved FVIII Function

Jie Gong, Yuchen Liu, Min Zhou, Lung-Ji Chang

Blood (2022) 140 (Supplement 1): 10650–10651.

https://doi.org/10.1182/blood-2022-159840

Published: 2022

Journal Articles

Whole Genome Sequencing Identifies a Recurrent Mutation in Complement Factor I ( CFI ) in Primary Myelofibrosis (PMF)

Brooke Sadler, Anna D Chorzalska, Dennis M Bonal, Gabe Haller, Alissa Oakes, Max Petersen, Yuchen Liu, Adam Olszewski, John L Reagan, Pamela C Egan, Rabin Niroula, Diana O Treaba, Gabriela Hobbs, Stephen T. Oh, Jorge Di Paola, Joanna E Baxter, Patrycja M Dubielecka

Blood (2021) 138 (Supplement 1): 1472.

https://doi.org/10.1182/blood-2021-154281

Published: 2021

Journal Articles

Improved Safety and Efficacy of a Multi-Target Chimeric Antigen Receptor Modified T Cell Therapy (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Rui Zhang, MSc, Yuhua Li, MD& PhD, Sanfang Tu, MD& PhD, Rui Huang, MD& PhD, Xun Lai, MD, Leping Zhang, MD PhD, Eugene E. Zvonkov, MD PhD, Valeriy G. Savchenko, MD PhD, Nelly G Gabeeva, PhD, Yuchen Liu, MSc, Yuchen Li, MSc, Cheng Jiao, MD PhD, Lan Deng, MD PhD, Xuan Zhou, MD, Hongyu Zhang, MD PhD, Wenli Zhang, MD, Lung-Ji Chang, PhD

Blood (2020) 136 (Supplement 1): 47.

https://doi.org/10.1182/blood-2020-141515

Published: 2020

Journal Articles

CAR2.0 Therapy for the Management of Post-Transplantation Relapse of B-Cell Acute Lymphoblastic Leukemia

Blood (2020) 136 (Supplement 1): 7.

https://doi.org/10.1182/blood-2020-141531

Published: 2020

Journal Articles

Rescue of a Terminally Ill Patient with Chemo-Refractory Acute Lymphoblastic Leukemia Carrying Bcr/Abl and TP53 Mutations Based on a 4th Generation CD19 Chimeric Antigen Receptor-Engineered T (CAR-T) Therapy

Ting Niu, MD PhD, Lung-Ji Chang, PhD, Jinrong Yang, MD, Yuchen Liu, MSc, Lujia Dong, MD, Wei Wang, PhD, Ting Liu, MD

Blood (2015) 126 (23): 5431.

https://doi.org/10.1182/blood.V126.23.5431.5431

Published: 2015

Journal Articles

Up-Regulation of CAR-T Cells after G-CSF and Dexamethasone Treatment in a Defuse Large B Cell Lymphoma Patient Receiving 4SCAR19 T Cell Therapy

Hongmei Jing, MD, Lung-Ji Chang, PhD, Mingyi Chen, MD PhD, Fang Bao, MD, Jing Wang, Wenming Wang, Yuanyuan Liu, Hao-Hsian Kuo, MSc, Yuchen Liu, MSc, Lujia Dong, MD

Blood (2015) 126 (23): 5130.

https://doi.org/10.1182/blood.V126.23.5130.5130

Published: 2015

Journal Articles

4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass

Lung-Ji Chang, PhD, Lujia Dong, MD, Jun Zhu, MD, Zhitao Ying, MD, Hao-Hsian Kuo, MSc, Yuchen Liu, MSc, Yu-Qin Song, MD, Xiao-Pei Wang, MD, Yong-Qian Jia, MD, Ting Niu, MD PhD, Ting Liu, MDPhD, Ling Pan, MD, Zhuo-Gang Liu, MD, Tong Li, MD, Ying-Chun Li, MD, Kun Yao, MD, Xiaoyan Ke, MD PhD, Hongmei Jing, MD, Fang Bao, MD

Blood (2015) 126 (23): 264.

https://doi.org/10.1182/blood.V126.23.264.264

Published: 2015

NARROW

A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed/refractory acute myeloid leukemia

Overcoming Venetoclax (Ven) Resistance through Glutamine (Gln) Depletion: Final Analysis of the Phase 1 Trial of Ven and Pegcrisantaspase (PegC) Combination in Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML)

Targeting the JAK2V617F Hematopoietic Stem Cell through Beta1 Integrin

Phase 1 Dose Escalation Trial of Pegcrisantaspase in Combination with Venetoclax in Adults with Relapsed or Refractory Acute Myeloid Leukemia

Sequential GD2 Chimeric Antigen Receptor T Cell Therapy (4SCAR2.0-GD2) for the Treatment of Refractory/Relapsed Neuroblastoma

Pro-Active 4SCAR2.0 Therapy with NGS-MRD Disease Monitoring in High-Risk B Cell Leukemia Management

Improved Lentiviral In Vivo Gene Therapy for Chronic Granulomatous Disease

Intravenous Lentiviral Gene Therapy for Hemophilia a: Endothelial-Specific Expression and Increased Glycosylation for Improved FVIII Function

Whole Genome Sequencing Identifies a Recurrent Mutation in Complement Factor I ( CFI ) in Primary Myelofibrosis (PMF)

Improved Safety and Efficacy of a Multi-Target Chimeric Antigen Receptor Modified T Cell Therapy (4SCAR2.0) Against Relapsed or Refractory Lymphomas

CAR2.0 Therapy for the Management of Post-Transplantation Relapse of B-Cell Acute Lymphoblastic Leukemia

Rescue of a Terminally Ill Patient with Chemo-Refractory Acute Lymphoblastic Leukemia Carrying Bcr/Abl and TP53 Mutations Based on a 4th Generation CD19 Chimeric Antigen Receptor-Engineered T (CAR-T) Therapy

Up-Regulation of CAR-T Cells after G-CSF and Dexamethasone Treatment in a Defuse Large B Cell Lymphoma Patient Receiving 4SCAR19 T Cell Therapy

4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only